Reporting owner · CIK 0001680739

Baynes Roy D.

Visual SEC Form 4 history across 3 companies, 9 transactions and 5 filings.

DIRAardvark Therapeutics, Inc.
Open-market mix
Latest filingAug 21, 2026, 11:45 PM
Filings5Form 4 records
Buying$00 purchases
Selling$540K2 sales
Net value−$540KBuys minus sells
Companies33 securities
Most recentAug 14, 2026grant

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-51Jan 251Feb 25Jan 26Aug 26

Net value flow

Buys minus sells

Jan 25
−$320K
Feb 25
−$220K
Jan 26
$0
Aug 26
$0

Transaction texture

Ownership and ticket size

Average P/S size$270K
Median P/S size$270K
Direct9
Indirect0
Aug 14, 2026grant

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern2Delayed Filingfiling-context1Derivative Transactionfiling-context3Direct Ownershipfiling-context9Large Holdings Increaseholdings2Large Holdings Reductionholdings2Repeat Sellerpattern110b5-1 Detectedfiling-context6

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Travere Therapeutics, Inc. on Feb 06, 2025 valued at $220,000.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Travere Therapeutics, Inc. on Feb 06, 2025 valued at $220,000.

Review SEC filing

Associated companies

Visual map of known reporting history

AARDAardvark Therapeutics, Inc.1 transactions · latest Aug 21, 2026, 11:45 PMNTRANatera, Inc.2 transactions · latest Feb 04, 2026, 01:35 AMTVTXTravere Therapeutics, Inc.6 transactions · latest Feb 10, 2025, 11:04 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
AARDBaynes Roy D.
DIR
grant44.9k$0A
Delayed Filing Derivative Transaction Direct Ownership+1
+0.9%08/2108/14
NTRABaynes Roy D.
DIR
grant70—A
Direct Ownership
+0.6%02/0401/30
TVTXBaynes Roy D.
DIR
exercise10b5-110.0k$0M
Derivative Transaction Direct Ownership 10b5-1 Detected
—02/10/202502/06/2025
TVTXBaynes Roy D.
DIR
sale10b5-110.0k-$22.0MS
Cluster Selling Direct Ownership Large Holdings Reduction+2
—02/10/202502/06/2025
TVTXBaynes Roy D.
DIR
exercise10b5-110.0k$17.4MM
Direct Ownership 10b5-1 Detected
—02/10/202502/06/2025
NTRABaynes Roy D.
DIR
grant92—A
Direct Ownership
—02/05/202501/31/2025
TVTXBaynes Roy D.
DIR
exercise10b5-116.0k$0M
Derivative Transaction Direct Ownership 10b5-1 Detected
—01/24/202501/23/2025
TVTXBaynes Roy D.
DIR
sale10b5-116.0k-$32.0MS
Cluster Selling Direct Ownership Large Holdings Reduction+1
—01/24/202501/23/2025
TVTXBaynes Roy D.
DIR
exercise10b5-116.0k$28.0MM
Direct Ownership Large Holdings Increase 10b5-1 Detected
—01/24/202501/23/2025

Baynes Roy D. Insider Activity FAQ

SEC Form 4 context

Who is Baynes Roy D.?

Baynes Roy D. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001680739.

Which companies has Baynes Roy D. reported transactions for?

Aardvark Therapeutics, Inc., Natera, Inc., Travere Therapeutics, Inc.

When was Baynes Roy D.'s latest insider buy?

No open-market insider purchase is available for this period.

When was Baynes Roy D.'s latest insider sale?

sale at Travere Therapeutics, Inc. on Feb 06, 2025 valued at $220,000.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.